{"id":70541,"date":"2023-02-16T18:39:31","date_gmt":"2023-02-16T17:39:31","guid":{"rendered":"https:\/\/www.fedaiisf.it\/?p=70541"},"modified":"2023-02-16T18:52:31","modified_gmt":"2023-02-16T17:52:31","slug":"aifa-aggiorna-le-liste-di-trasparenza","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/aifa-aggiorna-le-liste-di-trasparenza\/","title":{"rendered":"AIFA updates the Transparency Lists"},"content":{"rendered":"<p><a href=\"https:\/\/www.aifa.gov.it\/-\/aifa-aggiorna-le-liste-di-trasparenza-21\" target=\"_blank\" rel=\"noopener\">AIFA press release. February 15, 2023<\/a><\/p>\n<p><span style=\"font-size: 14pt;\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-70545 alignright\" src=\"https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2023\/02\/liste-di-trasparenza.png\" alt=\"\" width=\"408\" height=\"257\" srcset=\"https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2023\/02\/liste-di-trasparenza.png 1011w, https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2023\/02\/liste-di-trasparenza-300x189.png 300w, https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2023\/02\/liste-di-trasparenza-768x484.png 768w\" sizes=\"auto, (max-width: 408px) 100vw, 408px\" \/>In order to allow the Regions and autonomous Provinces to apply the provisions of art. 9, paragraph 5 of the Law of 8 August 2002, n. 178 the Italian Medicines Agency publishes, pursuant to the AIFA Directorial Determination n. 166 of 10 February 2021 published in the Official Gazette - General Series n. 39 and in compliance with the orders of the Council of State n. 583\/2023, 596\/2023 and 605\/2023, the<strong>The list of medicines and their reference prices updated on February 15, 2023<\/strong> inclusive of the reduction envisaged pursuant to the AIFA determination of 3 July 2006, of the additional<br \/>\n<img loading=\"lazy\" decoding=\"async\" class=\"wp-image-70546 alignleft\" src=\"https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2023\/02\/Commissioni-tecniche-AIFA.png\" alt=\"\" width=\"418\" height=\"181\" srcset=\"https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2023\/02\/Commissioni-tecniche-AIFA.png 1011w, https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2023\/02\/Commissioni-tecniche-AIFA-300x130.png 300w, https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2023\/02\/Commissioni-tecniche-AIFA-768x333.png 768w\" sizes=\"auto, (max-width: 418px) 100vw, 418px\" \/>reduction of the 5% pursuant to the AIFA determination of 27 September 2006, of the art. 9 paragraph 1, of the Law of 28 February 2008 n. 31 (Payback) and paragraph 9 of art. 11 of Legislative Decree 78\/2010 converted with amendments by the Law of 30 July 2010, n. 122.<\/span><\/p>\n<p><span style=\"font-size: 14pt;\">The lists are published in compliance with the criteria defined by the AIFA Directorial Decision n. 166\/2021 and in compliance with the Sentences of the Council of State n. 5858\/2022 and 5863\/2022.<\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><a href=\"https:\/\/www.aifa.gov.it\/documents\/20142\/1826403\/Lista_farmaci_equivalenti_Principio_Attivo_15.02.2023.pdf\" target=\"_blank\" rel=\"noopener\">List by Active Principle<\/a><\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><a href=\"https:\/\/www.aifa.gov.it\/documents\/20142\/1826403\/Lista_farmaci_equivalenti_Nome_Commerciale_15.02.2023.pdf\" target=\"_blank\" rel=\"noopener\">List by business name<\/a><\/span><\/p>\n<p>Related news: <a href=\"https:\/\/www.aifa.gov.it\/sites\/default\/files\/2017-03-30_Corso_di_alta_form_AboutPharma_FRANCESCA2.pdf\" target=\"_blank\" rel=\"noopener\">The role of AIFA in the negotiation and regulation of the price of medicines<\/a><\/p>\n<p id=\"cont_art_title\"><a href=\"http:\/\/www.farmacista33.it\/carenza-antibiotici-produttori-di-generici-nuove-politiche-di-prezzo-e-monitoraggio-fabbisogni\/politica-e-sanita\/news--63800.html\" target=\"_blank\" rel=\"noopener\">Shortage of antibiotics, producers of generics: new pricing policies and needs monitoring<\/a><\/p>\n<p>&nbsp;<\/p>","protected":false},"excerpt":{"rendered":"<p>Comunicato AIFA . 15 febbraio 2023 Al fine di consentire alle Regioni e Province autonome una omogenea applicazione di quanto previsto dall\u2019art. 9, comma 5 della Legge 8 agosto 2002, n. 178 l\u2019Agenzia Italiana del Farmaco pubblica, ai sensi della Determinazione direttoriale AIFA n. 166 del 10 febbraio 2021 pubblicata nella Gazzetta Ufficiale- Serie Generale &hellip;<\/p>","protected":false},"author":4,"featured_media":70548,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[49,31],"class_list":["post-70541","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-aifa","tag-generici"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/70541","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=70541"}],"version-history":[{"count":5,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/70541\/revisions"}],"predecessor-version":[{"id":70549,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/70541\/revisions\/70549"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/70548"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=70541"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=70541"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=70541"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}